Trials / Completed
CompletedNCT02340780
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
A Phase II Study of Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.
Detailed description
Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment. The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buparlisib |
Timeline
- Start date
- 2015-04-27
- Primary completion
- 2018-11-21
- Completion
- 2020-04-28
- First posted
- 2015-01-19
- Last updated
- 2023-08-22
- Results posted
- 2019-08-13
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02340780. Inclusion in this directory is not an endorsement.